top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Andrew Ashe Biography and Net Worth

Insider of Verve Therapeutics

Andrew Ashe is president and chief operating officer of Verve Therapeutics. Mr. Ashe is an accomplished biotech executive with over 20 years of experience in operations and legal management. Prior to joining Verve, he served as a senior executive and general counsel for several biotech companies, including Applied Genetic Technologies Corporation and Dyax Corp. During his tenure at Dyax, Mr. Ashe managed all legal and administrative functions during a period of growth in which market capitalization increased from $180 million to $6 billion. While at Dyax, he also established more than 75 revenue-generating collaborations with biotech and pharma companies in the United States, Europe, India, Australia, and Japan. Dyax was acquired in 2016. Previously, Mr. Ashe was a member of the business law practices at Prince Lobel Tye LLP and Nutter, McClennen & Fish LLP. Prior to attending law school, he served as a trading specialist and senior analyst at the American and New York Stock Exchanges. He holds a B.A. in finance from the Isenberg School of Management at University of Massachusetts and a J.D. from the George Washington University School of Law.

How old is Andrew D. Ashe?: Mr. Ashe is currently 57 years old. There are 5 older executives and no younger executives at Verve Therapeutics. The oldest executive at Verve Therapeutics is Dr. Burt A. Adelman M.D., Co-Founder & Independent Chairman of the Board, who is 72 years old. Learn More on Andrew D. Ashe's age.
How do I contact Andrew D. Ashe?: The corporate mailing address for Mr. Ashe and other Verve Therapeutics executives is , , . Verve Therapeutics can also be reached via phone at 617-603-0070 and via email at [email protected]. Learn More on Andrew D. Ashe's contact information.
Has Andrew D. Ashe been buying or selling shares of Verve Therapeutics?: Andrew D. Ashe has not been actively trading shares of Verve Therapeutics over the course of the past ninety days. Most recently, on Thursday, December 2nd, Andrew D. Ashe bought 4,000 shares of Verve Therapeutics stock. The stock was acquired at an average cost of $32.10 per share, with a total value of $128,400.00. Learn More on Andrew D. Ashe's trading history.
Who are Verve Therapeutics' active insiders?: Verve Therapeutics' insider roster includes Burt Adelman (Director), Andrew Ashe (Insider), Andrew Bellinger (Insider), and Sekar Kathiresan (CEO). Learn More on Verve Therapeutics' active insiders.
Are insiders buying or selling shares of Verve Therapeutics?: In the last twelve months, insiders at the sold shares 2 times. They sold a total of 2,068 shares worth more than $18,818.66. The most recent insider tranaction occured on April, 2nd when insider Joan Nickerson sold 1,514 shares worth more than $12,475.36. Insiders at Verve Therapeutics own 21.4% of the company. Learn More about insider trades at Verve Therapeutics.
Information on this page was last updated on 4/2/2024.

Andrew D. Ashe Insider Trading History at Verve Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/2/2021	Buy	4,000	$32.10	$128,400.00

Andrew D. Ashe Buying and Selling Activity at Verve Therapeutics

Verve Therapeutics Company Overview

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $6.58

$6.53

$6.92

50 Day Range

MA: $11.92

$6.58

$17.96

2 Week Range

Now: $6.58

$6.42

$21.42

Volume

1,003,755 shs

Average Volume

1,229,842 shs

Market Capitalization

$550.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.7